TG Therapeutics Inc TGTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:00 PM EDT
17.50quote price arrow down-0.22 (-1.24%)
Volume
1,255,388
52 week range
6.46 - 31.81
Loading...
  • Open17.72
  • Day High17.74
  • Day Low17.29
  • Prev Close17.72
  • 52 Week High31.81
  • 52 Week High Date05/17/23
  • 52 Week Low6.46
  • 52 Week Low Date10/16/23

Key Stats

  • Market Cap2.705B
  • Shares Out154.54M
  • 10 Day Average Volume4.23M
  • Dividend-
  • Dividend Yield-
  • Beta2.33
  • YTD % Change2.66

KEY STATS

  • Open17.72
  • Day High17.74
  • Day Low17.29
  • Prev Close17.72
  • 52 Week High31.81
  • 52 Week High Date05/17/23
  • 52 Week Low6.46
  • 52 Week Low Date10/16/23
  • Market Cap2.705B
  • Shares Out154.54M
  • 10 Day Average Volume4.23M
  • Dividend-
  • Dividend Yield-
  • Beta2.33
  • YTD % Change2.66

RATIOS/PROFITABILITY

  • EPS (TTM)0.22
  • P/E (TTM)79.37
  • Fwd P/E (NTM)-330.19
  • EBITDA (TTM)48.527M
  • ROE (TTM)43.93%
  • Revenue (TTM)289.334M
  • Gross Margin (TTM)93.53%
  • Net Margin (TTM)14.24%
  • Debt To Equity (MRQ)63.29%

EVENTS

  • Earnings Date07/30/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On TG Therapeutics Inc

 

Profile

MORE
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting...
Michael Weiss J.D.
Chairman of the Board, President, Chief Executive Officer
Sean Power
Chief Financial Officer, Treasurer, Corporate Secretary
Address
3020 Carrington Mill Blvd., Suite 475
Morrisville, NC
27560-5435
United States

Top Peers

SYMBOLLASTCHG%CHG
DNLI
Denali Therapeutics Inc
20.57-0.29-1.37%
TWST
Twist Bioscience Corp
47.08-1.28-2.65%
IMCR
Immunocore Holdings PLC
54.47-1.54-2.75%
ADMA
ADMA Biologics Inc
9.10UNCHUNCH
MOR
MorphoSys AG
19.26+0.76+4.11%